Accutar Biotechnology announces fast track designation granted by FDA to AC0176 for the treatment of metastatic castration resistant prostate cancer

Accutar Biotechnology

1 June 2022 - Accutar Biotechnology today announced that the U.S. FDA has granted fast track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer with disease progression on or after treatment with androgen receptor signalling inhibitors. 

AC0176 is an orally bioavailable, chimeric degrader molecule targeting the androgen receptor.

Read Accutar Biotechnology press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track